Alkermes to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

05/31/2023 - 04:00 PM

DUBLIN, May 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chats at two upcoming investor conferences.

Jefferies Healthcare Conference
Date/Time: Wednesday, June 7, 2023 at 10:00 a.m. EDT (3:00 p.m. BST)

Goldman Sachs 44^th Annual Global Healthcare Conference
Date/Time: Monday, June 12, 2023 at 9:20 a.m. PDT (12:20 p.m. EDT/5:20 p.m. BST)

The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has a research and development center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

Alkermes Contact:
Jamie Bernard
Investor Relations
+1 781 873 2402